Drug Profile
GSK 256066
Alternative Names: 256066; GSK256066Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Amides; Aminoquinolines; Antiallergics; Antiasthmatics; Phenyl ethers; Small molecules; Sulfones
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Seasonal allergic rhinitis
Most Recent Events
- 31 Dec 2011 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Estonia, Finland, Germany, Netherlands, Russia and Slovakia (Inhalation)
- 31 Dec 2009 Discontinued - Phase-II for Asthma in United Kingdom, New Zealand and South Africa (Inhalation)
- 31 Dec 2008 Discontinued - Phase-II for Seasonal allergic rhinitis in Austria and Germany (Intranasal)